Zentalis Pharmaceuticals (ZNTL) Equity Ratio (2022 - 2025)
Zentalis Pharmaceuticals (ZNTL) has 3 years of Equity Ratio data on record, last reported at 0.78 in Q4 2024.
- For Q4 2024, Equity Ratio fell 1.17% year-over-year to 0.78; the TTM value through Dec 2024 reached 0.78, down 1.17%, while the annual FY2024 figure was 0.78, 1.17% down from the prior year.
- Equity Ratio reached 0.78 in Q4 2024 per ZNTL's latest filing, roughly flat from 0.79 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.84 in Q2 2023 and bottomed at 0.78 in Q2 2024.
- Average Equity Ratio over 3 years is 0.8, with a median of 0.79 recorded in 2023.
- Peak YoY movement for Equity Ratio: rose 1.13% in 2023, then dropped 7.59% in 2024.
- A 3-year view of Equity Ratio shows it stood at 0.81 in 2022, then decreased by 2.14% to 0.79 in 2023, then fell by 1.17% to 0.78 in 2024.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.78 in Q4 2024, 0.79 in Q3 2024, and 0.78 in Q2 2024.